In MDS and younger patients with CMML (age <65 years), the presence of clonal TET2 mutations, in the absence of clonal ASXL1 mutations, have been associated with response to hypomethylating agents (5-azacitidine and decitabine).5, 23 Treatment data on our cohort of patients were incomplete and it is currently unknown as to whether this favorable impact was an effect of better responses to hypomethylating agents or not. This evidence concerns the gene ASXL1 and myelodysplastic syndrome.